Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 197 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... January 28, 2022 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers November 10, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine Predicting future breast cancer with precision Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her...
